Risk of COVID-19 infection in long-term survivors of blood or marrow transplantation: a BMTSS report.


Journal

Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425

Informations de publication

Date de publication:
27 Jun 2023
Historique:
accepted: 17 01 2023
received: 15 12 2022
medline: 19 6 2023
pubmed: 2 2 2023
entrez: 1 2 2023
Statut: ppublish

Résumé

There is limited information regarding COVID-19 in long-term blood or marrow transplant (BMT) survivors. We leveraged the BMT Survivor Study (BMTSS) to address this gap. BMTSS included patients who underwent BMT at 1 of 3 sites in the United States between 1974 and 2014 and survived ≥2 years after BMT. A sibling cohort serves as a non-BMT comparison group. Participants (2430 BMT survivors; 780 non-BMT participants) completed the BMTSS survey between October 2020 and November 2021 about COVID-19 testing, risk mitigation behaviors, morbidity, and health care use. Median age at BMT was 46 years (range, 0-78 years) and median follow-up since BMT was 14 years (6-46 years); 76% were non-Hispanic White, 54% had received allogeneic BMT. The risk of COVID-19 infection was comparable for BMT survivors vs non-BMT participants (15-month cumulative incidence, 6.5% vs 8.1%; adjusted odd ratio [aOR] = 0.93; 95% confidence interval [CI], 0.65-1.33; P = .68). Among survivors, being unemployed (aOR 1.90; 95% CI, 1.12-3.23; P = .02; reference: retired) increased the odds of infection; always wearing a mask in public was protective (aOR = 0.49; 95% CI, 0.31-0.77; P = .002; reference: not always masking). When compared with COVID-positive non-BMT participants, COVID-positive BMT survivors had higher odds of hospitalization (aOR = 2.23; 95% CI, 0.99-5.05; P = .05); however, the odds of emergency department visits were comparable (aOR = 1.60; 95% CI = 0.71-3.58; P = .25). COVID-19 infection status did not increase the odds of hospitalization among BMT survivors (aOR = 1.32; 95% CI = 0.89-1.95; P = .17) but did increase the odds of emergency department visits (aOR = 2.63; 95% CI, 1.74-3.98; P <.0001). These findings inform health care providers about the management of care for long-term BMT survivors during the ongoing pandemic.

Identifiants

pubmed: 36724527
pii: 494291
doi: 10.1182/bloodadvances.2022009550
pmc: PMC9906674
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2843-2854

Subventions

Organisme : NCI NIH HHS
ID : R01 CA078938
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA213140
Pays : United States

Informations de copyright

© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Références

Ann Intern Med. 2021 Mar;174(3):362-373
pubmed: 33253040
Cancer Discov. 2020 Jun;10(6):783-791
pubmed: 32345594
Blood. 2010 Oct 28;116(17):3129-39; quiz 3377
pubmed: 20656930
Transpl Infect Dis. 2022 Apr;24(2):e13792
pubmed: 35030267
BMJ Open. 2020 Aug 11;10(8):e039849
pubmed: 32784264
Bone Marrow Transplant. 2015 Sep;50(9):1227-34
pubmed: 26052909
Biol Blood Marrow Transplant. 2013 Jul;19(7):1073-80
pubmed: 23583827
J Clin Oncol. 2021 Dec 1;39(34):3778-3788
pubmed: 34694886
JAMA Netw Open. 2022 Mar 1;5(3):e221754
pubmed: 35262712
Lancet Haematol. 2021 Mar;8(3):e185-e193
pubmed: 33482113
Lancet. 2020 Jun 27;395(10242):1973-1987
pubmed: 32497510
BMC Public Health. 2022 Jul 28;22(1):1436
pubmed: 35902818
Transplant Cell Ther. 2022 Nov;28(11):737-746
pubmed: 35902050
JAMA Pediatr. 2021 Feb 1;175(2):176-184
pubmed: 33226415
Bone Marrow Transplant. 2000 Jun;25(11):1191-6
pubmed: 10849532
Nat Rev Immunol. 2021 May;21(5):277-291
pubmed: 33097917
J Psychosoc Oncol. 2021;39(3):347-365
pubmed: 33624572
J Clin Oncol. 2022 May 1;40(13):1414-1427
pubmed: 35286152
J Natl Cancer Inst. 2021 Jun 1;113(6):691-698
pubmed: 33031532
J Clin Oncol. 2022 Apr 20;40(12):1281-1290
pubmed: 35226549
Biol Blood Marrow Transplant. 2013 Oct;19(10):1498-501
pubmed: 23906634
J Am Geriatr Soc. 2022 May;70(5):1314-1324
pubmed: 35211958
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
MMWR Morb Mortal Wkly Rep. 2020 Sep 11;69(36):1250-1257
pubmed: 32915166
JAMA Oncol. 2021 Feb 1;7(2):220-227
pubmed: 33300956
Transplant Cell Ther. 2022 Oct;28(10):696.e1-696.e7
pubmed: 35798233
Lancet Oncol. 2021 Oct;22(10):1416-1426
pubmed: 34454651
JAMA Oncol. 2022 Jan 1;8(1):69-78
pubmed: 34709356
Pediatr Blood Cancer. 2021 Mar;68(3):e28857
pubmed: 33355979

Auteurs

Emily E Johnston (EE)

Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, AL.
Division of Pediatric Hematology-Oncology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL.

Qingrui Meng (Q)

Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, AL.

Lindsey Hageman (L)

Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, AL.

Jessica Wu (J)

Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, AL.

Elizabeth Ross (E)

Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, AL.

Shawn Lim (S)

Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, AL.

Nora Balas (N)

Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, AL.

Alysia Bosworth (A)

Department of Population Sciences, City of Hope, Duarte, CA.

Hok Sreng Te (HS)

Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN.

Liton Francisco (L)

Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, AL.

Ravi Bhatia (R)

Division of Hematology, Oncology and Bone Marrow Transplantation, University of Alabama at Birmingham, Birmingham, AL.

Stephen J Forman (SJ)

Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA.

F Lennie Wong (FL)

Department of Population Sciences, City of Hope, Duarte, CA.

Saro H Armenian (SH)

Department of Population Sciences, City of Hope, Duarte, CA.

Daniel J Weisdorf (DJ)

Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN.

Wendy Landier (W)

Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, AL.
Division of Pediatric Hematology-Oncology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL.

Smita Bhatia (S)

Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, AL.
Division of Pediatric Hematology-Oncology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH